Charles Schwab Investment Management Inc. Invests $623,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Charles Schwab Investment Management Inc. bought a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 40,293 shares of the company’s stock, valued at approximately $623,000.

Artiva Biotherapeutics Trading Down 9.7 %

Shares of NASDAQ:ARTV opened at $9.97 on Thursday. The business has a 50-day moving average of $11.81. Artiva Biotherapeutics, Inc. has a fifty-two week low of $9.68 and a fifty-two week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.24). On average, analysts expect that Artiva Biotherapeutics, Inc. will post -4.68 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, August 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.25.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.